Voronoi, Inc.
Financials
Valuation Metrics
Voronoi, Inc.'s Market Cap is ₩2.5T. At end of 2025 it was ₩4.0T. Ranked #181 of 2,421 in KR market (top 7%), #34 of 1,640 on KOSDAQ (top 2%), #17 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.46T KRW | KR#181/2,421 Sec#17/231 |
| Revenue | 4.16B KRW | KR#2,352/2,421 Sec#202/231 |
| Net Income | -69.13B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 133.72B KRW | KR#1,583/2,421 Sec#123/231 |
| Net Assets | 69.18B KRW | KR#1,690/2,421 Sec#142/231 |
| Employees | 147 | KR#1,343/2,421 Sec#108/231 |
| Value | ||
| P/B | 35.56x | KR#2,412/2,421 Sec#229/231 |
| P/S | 591.04x | KR#2,407/2,421 Sec#222/231 |
| FCF Yield | -3.00% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -99.94% | KR#2,344/2,421 Sec#218/231 |
| ROA | -51.70% | KR#2,367/2,421 Sec#216/231 |
| Op. Margin | -1947.05% | KR#2,388/2,421 Sec#220/231 |
| Revenue Growth | 24.23% | KR#471/2,421 Sec#45/231 |
| Financial Health | ||
| Debt Ratio | 93.30% | KR#1,490/2,421 Sec#172/231 |
| Total Debt | 31.05B KRW | KR#1,212/2,421 Sec#90/231 |
| FCF | -73.74B KRW | KR#2,111/2,421 Sec#208/231 |
| Cash | 24.83B KRW | KR#1,114/2,421 Sec#75/231 |
| Current Ratio | 9.46x | KR#110/2,421 Sec#26/231 |
| Performance | ||
| 1Y Return | -15.63% | KR#1,136/2,421 Sec#74/231 |
| 1M Return | -24.72% | KR#2,332/2,421 Sec#216/231 |
| From 52W High | -64.63% | KR#2,023/2,421 Sec#163/231 |
| 1Y MDD | -72.27% | KR#2,084/2,421 Sec#182/231 |
| Trading | ||
| Volume | 106,939 shares | KR#752/2,421 Sec#70/231 |
| Trading Value | 14.21B KRW | KR#210/2,421 Sec#15/231 |
| Foreign Own. | 6.26% | KR#705/2,421 Sec#62/231 |
| Per Share | ||
| EPS | -3,732 KRW | KR—/2,421 Sec—/231 |
| BPS | 3,735 KRW | KR#1,717/2,421 Sec#126/231 |
Company Info
Established in 2015 in Songdo, Incheon, VORONOI is a new drug development venture company with its own medicinal chemistry research institute. It specializes in developing targeted anticancer drugs for conditions like lung and breast cancer, with VRN11 currently undergoing global clinical phase 1 trials after approvals in Korea, Taiwan, and Hong Kong. The company utilizes its Voronomix platform to accelerate drug development from target selection to candidate substance in 1-1.5 years, demonstrating competitiveness through five technology transfer achievements since 2020. VORONOI is headquartered in Yeonsu-gu, Incheon Metropolitan City.